BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
1939 results:

  • 1. Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study.
    Liu Y; Cui K; Ma W
    Cancer Med; 2024 May; 13(9):e6910. PubMed ID: 38746969
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Distinct Driver Pathway Enrichments and a High Prevalence of
    Tapia-Valladares C; Valenzuela G; González E; Maureira I; Toro J; Freire M; Sepúlveda-Hermosilla G; Ampuero D; Blanco A; Gallegos I; Morales F; Erices JI; Barajas O; Ahumada M; Contreras HR; González J; Armisén R; Marcelain K
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731914
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Apoptotic effect of 5-fluorouracil-doxorubicin combination on colorectal cancer cell monolayers and spheroids.
    Bilgin S
    Mol Biol Rep; 2024 May; 51(1):603. PubMed ID: 38698270
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
    Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
    Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exploring the Key Signaling Pathways and ncRNAs in colorectal cancer.
    Lee YJ; Kim WR; Park EG; Lee DH; Kim JM; Shin HJ; Jeong HS; Roh HY; Kim HS
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674135
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.
    Dreikhausen L; Klupsch A; Wiest I; Xiao Q; Schulte N; Betge J; Boch T; Brochhausen C; Gaiser T; Hofheinz RD; Ebert M; Zhan T
    BMC Cancer; 2024 Apr; 24(1):526. PubMed ID: 38664720
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
    Ferretti S; Hamon J; de Kanter R; Scheufler C; Andraos-Rey R; Barbe S; Bechter E; Blank J; Bordas V; Dammassa E; Decker A; Di Nanni N; Dourdoigne M; Gavioli E; Hattenberger M; Heuser A; Hemmerlin C; Hinrichs J; Kerr G; Laborde L; Jaco I; Núñez EJ; Martus HJ; Quadt C; Reschke M; Romanet V; Schaeffer F; Schoepfer J; Schrapp M; Strang R; Voshol H; Wartmann M; Welly S; Zécri F; Hofmann F; Möbitz H; Cortés-Cros M
    Nature; 2024 May; 629(8011):443-449. PubMed ID: 38658754
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
    Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
    Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions.
    Navas F; Chocarro-Calvo A; Iglesias-Hernández P; Fernández-García P; Morales V; García-Martínez JM; Sanz R; De la Vieja A; García-Jiménez C; García-Muñoz RA
    J Med Chem; 2024 Apr; 67(8):6410-6424. PubMed ID: 38592014
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Biogenic Zinc Oxide Nanoparticles synthesized from
    Berehu HM; Patnaik S
    Nanotheranostics; 2024; 8(3):312-329. PubMed ID: 38577319
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
    D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
    Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
    Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
    Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.
    Li H; Feng H; Zhang T; Wu J; Shen X; Xu S; Xu L; Wang S; Zhang Y; Jia W; Ji X; Cheng X; Zhao R
    Mol Cancer; 2024 Mar; 23(1):59. PubMed ID: 38515149
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
    Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
    Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Differential genetic mutations and immune cell infiltration in high- and low-risk STAD: Implications for prognosis and immunotherapy efficacy.
    Deng YY; Sun Y; Wu SJ; Zhang TY; Yang J; Liu K
    J Cell Mol Med; 2024 Apr; 28(7):e18174. PubMed ID: 38494839
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Evaluating the role of wound-healing genes in conjunction with stool routine and serum tumor markers for colorectal cancer diagnosis and prognostic implications.
    Yu K; Fang X
    Int Wound J; 2024 Mar; 21(3):e14768. PubMed ID: 38446012
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells.
    Kakafika MG; Lyta AA; Gavriilidis GI; Tsiftsoglou SA; Miliotou AN; Pappas IS; Vizirianakis IS; Papadopoulou LC; Tsiftsoglou AS
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426621
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 97.